Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmented BFM Regimen in High Risk Acute Lymphoblastic Leukemia (ALinC 17)
NCT00005603Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2000
- Primary completion
- Sep 2005
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of asparaginase escherichia coli, cyclophosphamide, cytarabine, daunorubicin, dexamethasone in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Mar 2000; status: completed.
02
Drugs
asparaginase escherichia colicyclophosphamidecytarabinedaunorubicindexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00005603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005603.